TTM 002
Alternative Names: TTM-002Latest Information Update: 26 Mar 2024
Price :
$50 *
At a glance
- Originator Kyoto University
- Developer Time therapeutics
- Class Antidementias; Neuroprotectants
- Mechanism of Action CACNA2D1 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Tauopathies
Most Recent Events
- 29 Feb 2024 Early research in Tauopathies in Japan (Time therapeutics pipeline, February 2024)